Results 31 to 40 of about 9,958,775 (335)

Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

open access: yesAntibody Therapeutics, 2018
The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody ...
D. Zahavi   +3 more
semanticscholar   +1 more source

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers.

open access: yesTrends in immunology, 2022
Bi-, tri- and multispecific antibodies have enabled the development of targeted cancer immunotherapies redirecting immune effector cells to eliminate malignantly transformed cells.
S. Pinto   +4 more
semanticscholar   +1 more source

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

open access: yesHaematologica, 2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof   +8 more
doaj   +1 more source

Imlifidase Inhibits HLA Antibody-Mediated NK Cell Activation and Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) In Vitro.

open access: yesTransplantation, 2019
BACKGROUND Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important pathway responsible for antibody-mediated rejection (AMR). Imlifidase (IdeS) cleaves human IgG into F(ab')2 and Fc fragments, potentially inhibiting ADCC.
Shi-Li Ge   +6 more
semanticscholar   +1 more source

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

open access: yesCells, 2020
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a ...
Ilaria Saltarella   +9 more
doaj   +1 more source

Real time assays for quantifying cytotoxicity with single cell resolution. [PDF]

open access: yesPLoS ONE, 2013
A new live cell-based assay platform has been developed for the determination of complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC), and overall cytotoxicity in human whole blood.
Sonny C Hsiao   +5 more
doaj   +1 more source

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy

open access: yesCancer immunology research, 2016
It is not clear which patients with mCRC will benefit from treatment with cetuximab, an antibody to the EGF receptor. Cetuximab-mediated ADCC and NK-cell cytotoxicity ex vivo correlated with FcγR polymorphisms and could predict cetuximab responsiveness ...
A. Trotta   +13 more
semanticscholar   +1 more source

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies

open access: yesJournal of Virology, 2016
Although antibodies to the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein have been studied extensively for their ability to block viral infectivity, little data are currently available on nonneutralizing functions of these antibodies,
Benjamin von Bredow   +8 more
semanticscholar   +1 more source

The role of coronin 1 during cell mediated immune responses [PDF]

open access: yes, 2013
Coronin 1 is one of 7 mammalian isoforms member of the evolutionary conserved WD40-repeat proteins that are involved in a variety of activities such a cell migration and cytokinesis.
Tchang, Vincent Sam Yong
core   +1 more source

Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity

open access: yesFrontiers in Immunology, 2017
Immunotherapy using broadly neutralizing antibodies (bNAbs) endowed with Fc-mediated effector functions has been shown to be critical for protecting or controlling viral replication in animal models.
Nicole F. Bernard   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy